PMGC Holdings Inc.ELABEarnings & Financial Report
Nasdaq · Pharmaceutical Preparations
ELAB Q3 FY2025 Key Financial Metrics
Revenue
$285.9K
Gross Profit
$78.0K
Operating Profit
$-2.2M
Net Profit
$-2.6M
Gross Margin
27.3%
Operating Margin
-769.0%
Net Margin
-907.3%
YoY Growth
-45.8%
PMGC Holdings Inc. Q3 FY2025 Financial Summary
PMGC Holdings Inc. reported revenue of $285.9K (down 45.8% YoY) for Q3 FY2025, with a net profit of $-2.6M (down 72.8% YoY) (-907.3% margin). Cost of goods sold was $207.9K, operating expenses totaled $2.3M.
Key Financial Metrics
| Total Revenue | $285.9K |
|---|---|
| Net Profit | $-2.6M |
| Gross Margin | 27.3% |
| Operating Margin | -769.0% |
| Report Period | Q3 FY2025 |
PMGC Holdings Inc. Quarterly Revenue & Net Profit History
PMGC Holdings Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $285.9K | -45.8% | $-2.6M | -907.3% |
| Q3 FY2024 | $527.5K | -4.9% | $-1.5M | -284.6% |
| Q2 FY2024 | $605.5K | — | $-1.4M | -233.3% |
| Q1 FY2024 | $614.6K | — | $-1.4M | -227.4% |
| Q3 FY2023 | $554.7K | — | $-783.0K | -141.2% |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Revenue | $554654 | $614563 | $605529 | $527478 | $285948 |
| YoY Growth | N/A | N/A | N/A | -4.9% | -45.8% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Assets | $1.58B | $4.2M | $5.1M | $11.2M | $14.9M |
| Liabilities | $1.75B | $1.7M | $2.4M | $2.7M | $6.4M |
| Equity | $-163895 | $2.5M | $2.6M | $8.6M | $8.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-2.3M | $-780689 | $-381678 | $-1.5M |